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INTRODUCTION
X-linked severe combined immunodeficiency (X-SCID)
is a rare, life-threatening disease that is characterized by marked
impairment of both cellular and humoral immunity (1). Hu-
man X-SCID occurs in as many as 50% of patients with pri-
mary SCID; patients have complete or marked deficiency of
T cells but carry a normal or slightly increased number of B
cells, despite a deficiency in specific antibody responses (2).
Infants with SCID have no tonsils, rarely have detectable peri-
pheral lymph nodes, and have a small, poorly differentiated
thymus gland. Without bone marrow transplantation (BMT),
affected patients suffer severe and persistent infections, often
with opportunistic pathogens, and generally die in infancy. 
The abnormal gene was mapped to the Xq13 region, and
later identified as the gene encoding the common gamma ( c)
chain (3, 4) that is common to the cell-surface receptors for
six interleukin (IL) molecules (IL-2, 4, 7, 9, 15, and 21) (2-5).
Based on the amino acid sequence, the complete cDNA clone
encoding the 64-kDa molecule was isolated and demonstrated
to be the cognate IL-2R chain (6, 7). The intracellular por-
tion of the  c chain is known to interact with Janus kinase 3
(Jak3), a signaling kinase that cooperates with other Jak and
STAT proteins in a complex signal transduction array (8, 9). 
Various mutations in the  c chain gene have been report-
ed in patients with X-SCID (10-15). However, little is known
about the clinical and immunological characteristics, or the
genetic polymorphism in Korean patients with X-SCID. Here,
we report the mutation identified in one Korean family with
X-SCID, along with prenatal diagnosis of the disease by RFLP
analysis. To our knowledge, this is the first report of the molec-
ular diagnosis of X-SCID in a Korean patient.
CASE REPORT
A 13-month-old boy was transferred to the Department of
Pediatrics, Chonnam National University Hospital, because
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X-linked Severe Combined Immunodeficiency Syndrome: The First
Korean Case with γ c Chain Gene Mutation and Subsequent Genetic
Counseling
X-linked severe combined immunodeficiency (X-SCID) is a rare, life-threatening
immune disorder, caused by mutations in the  c chain gene, which encodes an essen-
tial component of the cytokine receptors for interleukin-2 (IL-2), IL-4, IL-7, IL-9, IL-15,
and IL-21. A 13-month-old boy with recurrent infections who had reduced serum
immunoglobulin levels and decreased numbers of CD3, CD16/56 cells was evalu-
ated for  c chain gene mutation and protein expression. The patient had a C-to-T
point mutation at nucleotide position 690, one of the hot spots, resulting in a single
amino acid substitution of cysteine for arginine (R226C), as determined by direct
sequencing and PCR-RFLP. The patient’s mother was a heterozygous carrier. Per-
cutaneous umbilical cord blood sampling was performed at the 6-month of gesta-
tion in a subsequent pregnancy. As the immunophenotype of the fetus showed an
identical pattern, the pregnancy was terminated and genetic analysis of the abortus
confirmed recurrence. This is the first report of the molecular diagnosis of X-SCID
in Korea. Genetic analysis of the  c chain gene is useful for definite diagnosis and
genetic counseling for X-SCID.
Key Words : Severe Combined Immunodeficiency; Genetic Diseases, X-linked; Mutation; Genetic Counsel-
ing; Korea
Received : 18 December 2002
Accepted : 18 February 2003124 E.-K. Jo, S. Kumaki, D. Wei, et al.
of refractory, progressive pneumonia, and nodular skin lesions.
From the age of 7 months, he frequently visited his primary
physician because of recurrent upper respiratory infections. The
birth history was not contributory, but there was an infant
death history of unknown etiology for his uncle on the mother’s
side. The pedigree of the family is shown in Fig. 1A. He re-
ceived routine immunizations until 6 months of age, including
BCG.
On admission, he was immediately intubated and main-
tained with an artificial ventilator because of severe, bilater-
al pneumonia causing respiratory failure. The blood counts
on admission were: white blood cell, 45,100/ L (neutrophil
75.5%, lymphocyte 15.1%); hemoglobin, 14.4 g/dL; platelets
209,000/ L. His serum immunoglobulin profile was: IgG,
27.0 mg/dL (normal range, 345-1,236 mg/dL); IgM, 50.4
mg/dL (41-173 mg/dL); IgA, 22.9 mg/dL (14-159 mg/dL).
Flow cytometric analysis of lymphocyte immunophenotype
was: CD3 T cells, 2.5% (normal range, 60-85%); CD19 B
cells, 95.4% (8-20%); CD16/CD56 natural killer cells, 0.5%.
He was thus shown to have T-B+NK-SCID. 
On physical examination, he had no BCG scar, and biopsy
on the nodular skin lesion was later found to be a tuberculous
granuloma. He was treated with broad-spectrum antibiotics,
anti-tuberculosis agents, prophylactic antifungal agents, and
intravenous globulins. He gradually recovered and was weaned
off the ventilator on the 63rd hospital day. The recent blood
counts without infection were: 5,300/ L (neutrophils, 58.5%;
lymphocytes, 27.4%); hemoglobin, 12.5 g/dL; platelets
265,000/ L.
Blood samples were obtained from the patient and various
family members with written informed consent. Heparinized
venous blood samples from the patient and his family members
were fractionated on a Ficoll-Hypaque gradient to isolate
peripheral blood mononuclear cells (PBMCs). PBMCs were
washed twice in PBS and 0.02% NaN3, and analyzed by flow
cytometry for  c chain expression using the PE-conjugated rat
anti-human  c chain monoclonal antibody TUGh4 (Beckton-
Dickinson, Mountain View, CA, U.S.A.). Incubation with
unlabeled TUGh4 before the addition of labeled TUGh4 pro-
vided the background control staining. The method for im-
munofluorescence staining was the same as that described pre-
viously (16). As shown in Fig. 1B, PBMCs from the mother
showed  c chain expression on both CD3-and CD19-posi-
tive populations. In contrast, cells from the patient showed a
very depressed  c chain expression on CD3-and CD19-pos-
itive cells, suggesting both T and B cells from the patient did
not express  c chain on the cell surface (Fig. 1B).
The eight exons of the  c chain and surrounding genomic
sequences were amplified from genomic DNA as described
previously (12). As shown in Fig. 2A, we found a single base
substitution (C690T) at exon 5, resulting in an amino acid
change at codon 226 (R226C) in the patient. His mother was
found to have one mutant and one normal allele, indicating
that she was a heterozygous carrier. As the C-to-T substitu-
tion predicted the creation of a new AluI restriction endonu-
clease site, the sequencing results were further confirmed by
restriction fragment length polymorphism (RFLP) analysis
(Fig. 2B). The patient showed DNA cleavage with AluI (bands
of 179 and 133 bp), while the normal control was resistant
to AluI. The mother possessed an uncleaved (312 bp) and two
smaller bands identical to those in the patient, implying het-
erozygosity.
By RFLP analysis, we were able to perform a prenatal diag-
nosis on a male fetus. At the 24th week of gestation, 3 mL of
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Fig. 1. Pedigree and results of flow cytometric analyses of the X-
SCID family in this study. (A) Pedigree of the family. The closed
square and the closed lozenge indicate the patient and the male
fetus with X-SCID, respectively. The dotted circle indicates the car-
rier state. , male fetus therapeutically aborted after immunopheno-
typing and genetic analysis. (B) Flow cytometric analysis of the pa-
tient and his mother. The level of  c chain expression in PBMCs
was significantly reduced in the patient as compared with his mother.
The level of  c chain expression was evaluated by flow cytometric
analysis following immunostaining with mAb TUGh4. 
*
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Aumbilical cord blood was sampled percutaneously, and ana-
lyzed for lymphocyte phenotyping. The fetus had the same
T-B+NK- phenotype (CD3 T cells, 1.2%; CD19 B cells,
78.6%; CD16/CD56 natural killer cells, 1.2%). Fetal genomic
DNA isolated from amniotic cells was analyzed by RFLP for
exon 5. As shown in Fig. 2C, the fetal DNA showed the same
cleaved DNA pattern as the patient, while the healthy control
DNA showed the normal pattern. RFLP analysis demonstrat-
ed that the fetus had the same mutation as his brother, and
the pregnancy was terminated after lengthy counseling. The
patient is now being cared for at our outpatient clinic, await-
ing a stem cell transplant from an alternative donor, because
he does not have an HLA-matched sibling.
DISCUSSION
Here, we report the first mutation analysis of the  c chain
gene in a presumed X-SCID patient from a Korean family. The
patient had a single point mutation (C690T) at exon 5, result-
ing in an amino acid change at codon 226 (R226C). The Na-
tional Institutes of Health database of  c chain mutations lists
264 mutation entries, comprising 169 unique molecular events
(http://www.nhgri.nih.gov/DIR/GMBB/SCID/ IL2R Gbase.
html). Mutations have been identified throughout all eight
exons of the  c chain, the majority of which are missense muta-
tions, nonsense mutations, or splicing defects that give rise
to aberrant transcripts. The missense mutation found in this
study is not novel. The available data suggest that the codon
690 may be a hot spot for  c chain gene mutation, as report-
ed in several studies (10, 12-15). We did not examine the sta-
bility of mRNA or protein expression of the  c chain in this
study, but our previous study demonstrated that the  c chain
containing the point mutation was not expressed on the cell
surface because it was trapped in the Golgi apparatus and failed
to be transported to the cell surface (12). Further identification
of the locations and types of mutations in the  c chain gene
may lead to a better understanding of the functional domains
of the protein.
In addition, the patient showed a very little expression of  c
chain on both B and T cells. In a previous study, cell-surface
staining of patient-derived B cell lines with an anti- c chain
antibody showed no  c chain staining in 47% and trace am-
ounts in 32%, but normal intensity of staining in 21% of
patients (11). In another study, rapid protein analysis with flow
cytometry and immunoblotting were shown to be useful for
diagnosis of X-SCID and JAK3-deficient SCID. Although the
patients had mutations in the  c chain gene, some had trace
or normal levels of  c chain expression. Thus, these protein-
based assays have led to rapid molecular diagnoses of X-SCID
that have subsequently been confirmed by genetic analysis.
The male X-SCID patient in the present study had a clas-
sical, severe phenotype, and laboratory data showed low num-
bers of T cells, relatively well-preserved B cells, and reduced
NK cell numbers. X-SCID is a disease that is characterized
by severe lymphopenia and recurring persistent infections in
the first months of life (17). A human Jak3-deficiency disease
has similar clinical features to X-SCID (18), and the  c chain
and Jak3 signaling pathway have been suggested to be crucial
Mutation Analysis of X-SCID 125
B
C
12 3 4 56
500
400
300
200
100
500
400
300
200
100
12 34
Fig. 2. Sequence analysis showing a missense mutation of the
common  c chain gene ( c chain) in an X-SCID family. (A) Genomic
sequences encompassing a point mutation (C to T) in exon 5 of
the  c chain gene from the patient, carrier (mother), and normal
control (father) are shown. Arrow, C-to-T transversion. (B) RFLP anal-
ysis of the  c chain gene exon 5. Lanes 1 and 2, patient; Lanes 3
and 4, mother; Lanes 5 and 6, normal control. Lanes 1, 3, and 5
show the DNA fragments before restriction enzyme treatment, and Lanes 2, 4, and 6 show the DNA fragments after restriction enzyme treat-
ment. , Carrier; standard size markers, as indicated on the side. (C) RFLP analysis of amniotic cells. Lanes 1 and 2, fetus; Lanes 3 and 4,
normal control. Lanes 1 and 3 show the DNA fragments before restriction enzyme treatment, and Lanes 2 and 4 show the DNA fragments
after restriction enzyme treatment.
Patient
Mother
(Carrier)
Father
G TTTC GTG TTC GGAGCCGC TTTAAC CCAC TC TG
GT TT CGTG TTC GGAGCNGCT TTAACCCACTC TG
G TTT C GTGTTC GGAGC TGCTTTAAC CCAC TC TG
C to T
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for T cell development, and to contribute to the X-SCID phe-
notype (18). In addition, gene disruption of either IL-7 (19)
or the IL-7R subunit (20) has been shown to lead to severe
developmental perturbations. Thus, signaling defects in the
IL-7/IL-7R system resulting from changes in the  c chain may
account for the developmental anomalies that lead to X-SCID.
We also performed a prenatal diagnosis for this family, based
on our genetic findings. Most of the primary immunodeficien-
cy diseases can be diagnosed by means of screening for lym-
phopenia or for T cell deficiency in cord blood at birth. In
addition, fully defining the molecular defects of patients is
essential for genetic counseling of family members and pre-
natal diagnosis. 
In conclusion, we described here the molecular and cellular
identification of an X-SCID patient in a Korean family. Our
data emphasize that flow cytometric analysis is an important
and powerful assay that can contribute to diagnosis of X-SCID.
Further studies of X-SCID mutations should be compiled and
analyzed to provide data to clarify the correlation between
the severity of the disease and the types and locations of the
mutations in X-SCID patients.
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